THOUSAND OAKS, Calif., Nov. 16, 2019 /PRNewswire/ -- Amgen today announced a new analysis from the Repatha ® (evolocumab) cardiovascular outcomes (FOURIER) study that evaluates the effectiveness ...

Please contact Amgen Medinfo at 800-77-AMGEN (800-772-6436) or 844-REPATHA ... on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the ...

Please contact Amgen Medinfo at 800-77-AMGEN (800-772-6436) or 844-REPATHA ... on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the ...

Amgen's cholesterol drug Repatha has been given the green light in Europe, ... The drug is given in the form of a subcutaneous injection, either 140 mg every two weeks or 420mg once a month.

THOUSAND OAKS, Calif., Oct. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that effective Dec. 31, 2019, Repatha(®) (evolocumab), an innovative treatment for patients with high ...

Amgen AMGN announced that the FDA has approved its PCSK9 inhibitor, Repatha for different forms of familial hypercholesterolemia (FH) in pediatric patients.

At today's FDA advisory committee meeting, Amgen will present Repatha clinical trial data from approximately 6,800 patients, including more than 4,500 patients with high cholesterol in 10 Phase 3 ...

Amgen Inc <AMGN.O> on Tuesday said stock buybacks lifted its third-quarter earnings per share, but operating income fell as expenses rose and sales of some key products declined.

The pharmacy benefits manager announced today that Amgen's Repatha will be the one and only PCSK9 inhibitor to be offered in the CVS commercial formularies to treat patients with a hereditary form ...

Image source: Amgen via Flickr. The original biotech blue-chip stock, Amgen, has had nothing short of a phenomenal year. Even though its share price is up a pedestrian 3% year to date, the ...